Lymphoma Clinical Trials in San Francisco

Showing 321-334 of 334 trials

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619

RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of topotecan when given by intraventricular infusion in treating young patients with neoplastic meningitis due to leukemia, lymphoma, or solid tumors.

Brain and Central Nervous System TumorsCarcinoma of Unknown PrimaryLeukemia+2 more

Pediatric Brain Tumor Consortium19 participantsStarted Aug 2005

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +8 more locations

COMPLETEDPhase 2< 1 mile

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

NCT00516152

The primary objective of this study is to assess the safety and efficacy of performing unrelated stem cell transplants using intravenous busulfan and fludarabine as preparative therapy and tacrolimus plus methotrexate as the GVHD prophylaxis regimen. The goal is to demonstrate safety, aiming for a transplant related mortality rate (TRM) of \< or equal to 40% at 100 days. A TRM of \> or equal to 60% will be considered unacceptable. Another goal is to demonstrate efficacy by showing and overall survival of \>40% at 1-year following transplant.

Chronic Myeloid LeukemiaAcute Myelogenous LeukemiaMyelodysplasia+6 more

University of California, San Francisco36 participantsStarted Nov 2002

San Francisco, California, United States

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

Lymphoma Trials in Other Cities

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Other Conditions in San Francisco